Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:EPIXNASDAQ:JSPRNASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.270.0%$0.26$0.20▼$1.48$71.40M2.861.57 million shs162,112 shsEPIXESSA Pharma$1.68+0.6%$1.66$1.40▼$7.88$74.57M1.69338,581 shs27,851 shsJSPRJasper Therapeutics$5.69+0.2%$4.54$3.13▼$26.84$85.52M2.74294,825 shs72,686 shsMTEXMannatech$9.83+3.4%$9.76$6.75▼$16.49$18.69M1.064,404 shs1,088 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+0.74%-0.47%+3.80%-49.43%-72.96%EPIXESSA Pharma-0.60%+0.60%-5.65%-0.60%-73.78%JSPRJasper Therapeutics+11.15%+16.63%+10.29%-4.22%-76.55%MTEXMannatech-3.52%-8.92%-13.61%-17.79%+21.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.6359 of 5 stars4.23.00.00.02.70.80.0EPIXESSA Pharma1.9554 of 5 stars2.03.00.00.02.72.51.3JSPRJasper Therapeutics2.2572 of 5 stars3.51.00.00.03.41.70.6MTEXMannatech0.7553 of 5 stars0.04.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.43Hold$1.52456.17% UpsideEPIXESSA Pharma 2.00Hold$2.0019.05% UpsideJSPRJasper Therapeutics 3.00Buy$62.22992.96% UpsideMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, EPIX, JSPR, and ADAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.005/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.004/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/26/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.753/21/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.503/21/2025ADAPAdaptimmune TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.403/11/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$179.64M0.40N/AN/A$0.17 per share1.61EPIXESSA PharmaN/AN/AN/AN/A$2.68 per shareN/AJSPRJasper TherapeuticsN/AN/AN/AN/A$7.03 per shareN/AMTEXMannatech$115.04M0.16N/AN/A$5.64 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%8/11/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)JSPRJasper Therapeutics-$64.46M-$5.24N/AN/AN/AN/A-67.64%-58.53%8/12/2025 (Estimated)MTEXMannatech-$2.24M-$0.10N/A∞N/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)Latest MTEX, EPIX, JSPR, and ADAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025JSPRJasper Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/24/2025Q4 2024ADAPAdaptimmune Therapeutics-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMTEXMannatech$0.202.03%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics0.623.853.82EPIXESSA PharmaN/A33.1233.12JSPRJasper TherapeuticsN/A7.617.61MTEXMannatech0.441.250.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%EPIXESSA Pharma75.12%JSPRJasper Therapeutics79.85%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%EPIXESSA Pharma15.50%JSPRJasper Therapeutics2.70%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490261.52 million224.05 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableJSPRJasper Therapeutics2015.02 million14.60 millionOptionableMTEXMannatech2501.90 million1.10 millionNot OptionableMTEX, EPIX, JSPR, and ADAP HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Now Covered by Analysts at Wall Street ZenMay 23, 2025 | americanbankingnews.comMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.com(MTEX) Investment AnalysisOctober 6, 2024 | news.stocktradersdaily.comMannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in StockSeptember 12, 2024 | insidertrades.comDirector Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)September 11, 2024 | finance.yahoo.com(MTEX) Trading SignalsAugust 19, 2024 | news.stocktradersdaily.comMannatech Reports Financial Results for Second Quarter 2024August 13, 2024 | finance.yahoo.comHow To Trade (MTEX)July 29, 2024 | news.stocktradersdaily.com(MTEX) Long Term Investment AnalysisJuly 19, 2024 | news.stocktradersdaily.comMTEX Stock Earnings: Mannatech Reported Results for Q1 2024May 15, 2024 | investorplace.comMannatech Reports Financial Results for First Quarter 2024May 14, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, EPIX, JSPR, and ADAP Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.27 0.00 (-0.04%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.ESSA Pharma NASDAQ:EPIX$1.68 +0.01 (+0.60%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Jasper Therapeutics NASDAQ:JSPR$5.69 +0.01 (+0.23%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Mannatech NASDAQ:MTEX$9.83 +0.32 (+3.36%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
